Current Report Filing (8-k)
February 20 2018 - 2:05PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
February 14, 2018
|
ORAMED
PHARMACEUTICALS INC.
|
(Exact
name of registrant as specified in its charter)
|
DELAWARE
|
|
001-35813
|
|
98-0376008
|
(State
or Other Jurisdiction
|
|
(Commission
File Number)
|
|
(IRS
Employer
|
of
Incorporation)
|
|
|
|
Identification
No.)
|
Hi-Tech
Park 2/4 Givat Ram, PO Box 39098, Jerusalem, Israel
|
|
91390
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
+972-2-566-0001
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01. Entry into a Material Definitive Agreement.
On
February 14, 2018, Oramed Ltd. (the “Subsidiary”), a wholly-owned subsidiary of Oramed Pharmaceuticals Inc. (the “Company”),
entered into a Clinical Research Organization Services Agreement (the “Agreement”) with Integrium, LLC (“Integrium”),
effective as of November 1, 2017, to retain Integrium as a clinical research organization for the Subsidiary’s planned upcoming
three-month dose-ranging clinical trial. The trial will be conducted under an Investigational New Drug application with the U.S.
Food and Drug Administration, and is designed to assess the safety and evaluate the efficacy of ORMD-0801 on HbA1c on approximately
240 type 2 diabetic patients. The Agreement will terminate upon the satisfactory performance of all the services as contemplated
in the Agreement.
As
consideration for its services, the Subsidiary will pay Integrium a total amount of up to $7 million that will be paid over the
term of the engagement and based on the achievement of certain milestones.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ORAMED
PHARMACEUTICALS INC.
|
|
|
|
By:
|
/s/
Nadav Kidron
|
|
Name:
|
Nadav Kidron
|
|
Title:
|
President and CEO
|
|
|
|
February 20, 2018
|
|
|
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Apr 2023 to Apr 2024